Rebecca Critchley-Thorne, Ph.D., is Vice President, Research and Development and Co-Founder at Cernostics, Inc. She leads Cernostics' research and development of novel tests based on the proprietary TissueCypherT approach, which quantifies multiple key epithelial and stromal biomarkers in the context of tissue architecture for improved diagnostic, prognostic and predictive testing. Rebecca is a cancer immunologist with expertise in molecular and functional profiling of patient samples and was previously a Senior Scientist at Cellumen, Inc. in the Patient Sample Profiling Program, responsible for collaborative research on breast cancer diagnostics with the Mayo Clinic. She completed post-doctoral training at Stanford University in the Department of Medicine, Division of Hematology. Her research focused on functional profiling using multiplexed fluorescence immune biomarker analysis and also gene expression profiling of the immune system in cancer patient samples to identify mechanisms of tumor-induced immune dysfunction. She earned her PhD in Oncology from Imperial College, London, UK where her thesis was on recombinant E. coli as vectors for cancer prodrug therapy and immunotherapy.
Rebecca Critchley-Thorne, Ph.D., is Vice President, Research and Development and Co-Founder at Cernostics, Inc. She leads Cernostics' research and development of novel tests based on the proprietary TissueCypherT approach, which quantifies multiple key epithelial and stromal biomarkers in the context of tissue architecture for improved diagnostic, prognostic and predictive testing. Rebecca is a cancer immunologist with expertise in molecular and functional profiling of patient samples and was previously a Senior Scientist at Cellumen, Inc. in the Patient Sample Profiling Program, responsible for collaborative research on breast cancer diagnostics with the Mayo Clinic. She completed post-doctoral training at Stanford University in the Department of Medicine, Division of Hematology. Her research focused on functional profiling using multiplexed fluorescence immune biomarker analysis and also gene expression profiling of the immune system in cancer patient samples to identify mechanisms of tumor-induced immune dysfunction. She earned her PhD in Oncology from Imperial College, London, UK where her thesis was on recombinant E. coli as vectors for cancer prodrug therapy and immunotherapy.